Clinicopathological Characteristics and Predictive Markers of Early Gastric Cancer with Recurrence.
10.3346/jkms.2009.24.6.1158
- Author:
Jeong Won KIM
1
;
Ilseon HWANG
;
Mi Jung KIM
;
Se Jin JANG
Author Information
1. Department of Pathology, Seoul Veterans Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Early Gastric Cancer;
Recurrence;
Lymph Node Metastasis;
Immunohistochemistry;
Genes, erbB-2
- MeSH:
Adult;
Aged;
Animals;
Female;
Genes, erbB-2;
Humans;
Immunohistochemistry/methods;
Male;
Microarray Analysis/methods;
Middle Aged;
Multivariate Analysis;
*Neoplasm Recurrence, Local/metabolism/pathology;
Prognosis;
Risk Factors;
*Stomach Neoplasms/metabolism/pathology;
Tumor Markers, Biological/*metabolism
- From:Journal of Korean Medical Science
2009;24(6):1158-1164
- CountryRepublic of Korea
- Language:English
-
Abstract:
Early gastric cancer (EGC) is a "curable" disease with a high cure rate made possible through proper surgical treatment; nonetheless, some patients sustain a disease recurrence after curative resection. The aim of this study was to identify the clinicopathological characteristics of recurrent EGC and determine predictable immunohistochemical markers for recurrence. We investigated the clinicopathological features of 1,786 EGC cases, and using tissue microarray, the expression of c-erbB-2, EGFR, MLH1, MSH2, p53, and AQP1 was examined in group with recurrence and control group without recerrence. In the clinical analysis, 32 of 1,786 (1.79%) patients showed recurrence, with a 2.04% five-year cumulative recurrence rate. Age, submucosal invasion, and lymph node metastasis significantly correlated with tumor recurrence (P=0.044, 0.019, and <0.001, respectively). Multivariate analysis showed lymph node status and old age (> or =57 yr) as independent risk factors of recurrence. In a case-control study, immunopositivity for c-erbB-2 was significantly associated with disease recurrence (P=0.024). There is the probability that EGC patients with old age (> or =57 yr), lymph node metastasis, submucosal invasion, and c-erbB-2 immunopositivity will experience recurrence; therefore, it is critical that patients with these risk factors be followed-up closely and considered candidates for adjuvant treatment.
